| Literature DB >> 18457381 |
Nicolas Charrier1, Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon, Philip East, Julie Hawkins, Colin Howes, Ishrut Hussain, Phil Jeffrey, Graham Maile, Rosalie Matico, Julie Mosley, Alan Naylor, Alistair O'Brien, Sally Redshaw, Paul Rowland, Virginie Soleil, Kathrine J Smith, Sharon Sweitzer, Pam Theobald, David Vesey, Daryl S Walter, Gareth Wayne.
Abstract
BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18457381 DOI： 10.1021/jm800138h
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446